ClinicalTrials.gg
CompletedNCT02193334Updated Jun 5, 2019

Phase I/II Study of KP-100IT in Acute Spinal Cord Injury

A Phase 1/2 interventional study of KP-100IT and Placebo in Spinal Cord Injuries, sponsored by Kringle Pharma, Inc.. Completed at 2 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-06-05.

Sponsored by Kringle Pharma, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is randomized, double-blind, placebo-controlled Phase I/II study designed to evaluate safety and efficacy of KP-100IT, code of Hepatocyte Growth Factor (HGF) formulation for intrathecal injection, as a treatment for acute spinal cord injury. The study is conducted at two clinical sites in Japan.

02

Conditions studied

  • Spinal Cord Injuries

Keywords

  • Hepatocyte Growth Factor
  • HGF
  • KP-100IT
  • Intrathecal injection
03

In context

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 538 are open to participants now.

This study's enrollment of 45 is above the median of 24 across 1,634 interventional studies indexed under Spinal Cord Injuries.

Browse Spinal Cord Injuries studies →

Lead sponsor

Kringle Pharma, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age equal to or greater than 18 years and equal to or less than 75 years
  • Cervical spinal cord injury, and Grade A, B1 or B2 in the modified Frankel Scale at 72 hours since the injury
  • Subjects able to provide written informed concent, which may require a relative to sign if arm/hand function of the subject is compromised

Exclusion criteria

Exclusion Criteria:

  • Spinal cord injury at C1-C2 0r C2-C3 level
  • Patients not to able to start rehabilitation within a week by setup of respirator or other reason
  • First dose of the study drug will not be given within 78 hours since the injury
  • History of spinal cord injury or abnormality in spinal cavity. Or current considerable meningeal damage
  • Outcome assessment will not be conducted adequately through damage on injuries other than the injury
  • High-dose therapy within 30 days before the entry
  • Patients who have diseases such as serious liver disorder, renal disorder, hear disease, blood dyscrasia, metabolism disorder and infections
  • History of malignant tumor
  • Patients who participated in other clinical study within 30 days before the entry
  • Patients who have allergies to drug scheduled to be used in the study
  • Administration of the study drug to the area of spinal cord injury is not appropriate for example by intrathecal infections or intrathecal tumor
  • Patients not able to understand "" properly
  • Patients who are nursing or may be pregnant
  • Investigator considers that the patient is not appropriate for participating in the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Active comparator
    KP-100IT

    Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times

    Drug: KP-100IT

  • Placebo comparator
    Placebo

    Intrathecal injection of placebo starting at 72 hours since the injury and repeating weekly 5 times

    Drug: Placebo

Interventions

  • Also known as: Hepatocyte Growth Factor, HGF

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Number and degree of adverse events

    Adverse events will be judged by general condition, vital sign, electrocardiogram, MRI, blood chemistry, hematology, urinalysis, cerebrospinal fluid examination, and antibody formation

    Time frame: 24 weeks

  2. Change of ASIA (American Spinal Injury Association) motor score from baseline at 24 weeks

    Time frame: 24 weeks

Secondary outcomes

  1. Change of ASIA motor score from baseline at 12 weeks

    Time frame: 12 weeks

  2. Time-dependent change of ASIA motor score from baseline

    Time frame: 24 weeks

  3. Time-dependent change of ASIA sensory score from baseline

    Time frame: 24 weeks

  4. Time-dependent grade change of modified Frankel scale from baseline

    Time frame: 24 weeks

  5. Time-dependent change of P-100 concentration in plasma and cerebrospinal fluid

    Time frame: 6 weeks

07

Study locations

2 sites
  • Spinal Injuries Center
    Iizuka, Fukuoka 820-8508, Japan
  • Hokkaido Chuo Rosai Hospital Sekison Center
    Bibai, Hokkaido 072-0015, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Dec 2017, 41 months.

Of 24 phase 1/2 interventional studies under Spinal Cord Injuries, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2014
First posted
Jul 17, 2014
StartActual
Jun 30, 2014
Primary completionActual
Dec 21, 2017
CompletionActual
Jul 31, 2018
Last update
Jun 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02193334
Lead sponsor
Kringle Pharma, Inc.
Responsible party
Sponsor
First posted
Jul 17, 2014
Start date
Jun 30, 2014
Primary completion
Dec 21, 2017
Completion
Jul 31, 2018
Last update
Jun 5, 2019

Study contacts

Etsuro HASHIMURA
study director · Kringle Pharma, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KP-100IT

Start the discussion